Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Autologous Cell Therapy Market 

5.1. COVID-19 Landscape: Autologous Cell Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Autologous Cell Therapy Market, By Source

8.1. Autologous Cell Therapy Market Revenue and Volume, by Source, 2024-2033

8.1.1 Epidermis

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Bone Marrow

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Mesenchymal Stem Cells

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Haematopoietic Stem Cells

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Chondrocytes

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

8.1.6. Others

8.1.6.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Autologous Cell Therapy Market, By Application

9.1. Autologous Cell Therapy Market Revenue and Volume, by Application, 2024-2033

9.1.1. Cancer

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Cardiovascular Disorders

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Neurodegenerative Disorders

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Autoimmune Disorders

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Orthopedics

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

9.1.6. Wound Healing

9.1.6.1. Market Revenue and Volume Forecast (2021-2033)

9.1.7. Others

9.1.7.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Autologous Cell Therapy Market, By End-Use 

10.1. Autologous Cell Therapy Market Revenue and Volume, by End-Use, 2024-2033

10.1.1. Hospitals & Clinics

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Ambulatory Centers

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Academics & Research

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Autologous Cell Therapy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

Chapter 12. Company Profiles

12.1. Autolus Therapeutics

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Lineage Cell Therapeutics, Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Sangamo Therapeutics

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Holostem Terapie Avanzate S.r.l.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Vericel Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Opexa Therapeutics

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. BrainStorm Cell Therapeutics

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Pharmicell Co., Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Bayer AG

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Daiichi Sankyo Co., Ltd

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms